Clinical trial
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years…
NCT00163618 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00163618 |
|---|---|
| Title | Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children |
| Official title | Multicenter Phase IV Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Encephalitis, Tick-borne |
| Intervention type | Biological |
| Interventions | Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl |
| Start date | Jun 1, 2005 |
| Completion | Jul 1, 2006 |
| First posted | Sep 14, 2005 |
| Last update posted | May 21, 2015 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: